H2 inhalation therapy in patients with moderate COVID-19 (H2COVID): a prospective ascending-dose phase I clinical trial.
C Salomez-Ihl, J Giai, M Barbado, A Paris, S Touati, J P Alcaraz, S Tanguy, C Leroy, A Lehmann, B Degano, M Gavard, P Bedouch, P Pavese, A Moreau-Gaudry, M Roustit, F Boucher, P Cinquin, J P Brion · Antimicrobial agents and chemotherapy · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 12 patients, every patient showed clinical improvement and excellent tolerance to H₂ therapy. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 12 patients. Every patient showed clinical improvement and excellent tolerance to H₂ therapy.
What the Researchers Studied
The researchers studied 12 patients. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
3.6% inhaled H₂ concentration. Every patient showed clinical improvement and excellent tolerance to H₂ therapy. The authors concluded that the maximum tolerated duration is at least 3 days.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 12 patients. The reported sample size was 19. The study used a human clinical study. The reported hydrogen concentration was 3.6% inhaled H₂ concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.